Merck & Co. Inc. (NYSE:MRK) is one of the best value stocks in Goldman Sachs’ portfolio. On September 19, the company announced FDA approval for KEYTRUDA QLEX injection, the first subcutaneous version of its blockbuster cancer drug KEYTRUDA. Unlike the traditional intravenous (IV) form, QLEX can be administered subcutaneously (under the skin) in as little as one minute, providing patients and doctors with a faster and more convenient option. Merck’s (MRK) Oncology Portfolio Gets Shot in the Arm with QLEX ...